Coxsackieviruses are non-enveloped viruses belonging to the picornaviridae family and enterovirus genus that possess linear single-stranded RNA as their genetic material. Based on their pathogenecity tested on mice, these are categorized into group A and group B viruses. Group A viruses are known to cause skin and mucous membrane infections, leading to disorders such as herpangina, hand-foot-and-mouth (HFM) disease, and acute hemorrhagic conjunctivitis (AHC). Group B viruses infect the pancreas, liver, and heart, leading to various conditions such as pericarditis, hepatitis, myocarditis, and pleurodynia. According to Centers for Disease Control and Prevention (CDC) estimates, coxsackievirus infections accounted for around 25% of the neonatal enterovirus infections reported from 1983 to 2003. People from all age groups get infected by coxsackievirus; however, children are more susceptible to the infection. Fetuses or newborns are at a high risk of infection if their mother gets infected during pregnancy. These viruses are found in the feces, fluid in blisters, nasal secretions, and saliva of infected patients. Patients infected with coxsackievirus are diagnosed by the appearance of blisters on the hands, mouth, and feet. In rare instances, viral identification tests can be performed which involves the use of real time-PCR for amplification of the DNA sample. This test distinguishes the virus at the genus, species, and subtype level of nomenclature. Tylenol (acetaminophen) is usually administered for symptomatic treatment to reduce fever; other treatment options include Benadryl (diphenhydramine).
Major factors driving the global coxsackievirus diagnostics market are increase in incidence of coxsackievirus infections, surge in awareness among the people, and rigorous government initiatives to reduce the incidence of these infections. Lack of resources and accessibility in remote areas is one of the key factors likely to hamper the growth of the coxsackievirus diagnostics market. Moreover, development of more sensitive, efficient, and yet simple rapid diagnostic systems that can be applied to direct and indirect diagnosis remains a challenge in the coxsackievirus diagnostics market.
The global coxsackievirus diagnostics market can be segmented based on type of diagnostic test, end-user, and region. In terms of type of diagnostic test, the coxsackievirus diagnostics market can be classified into DNA probes, monoclonal antibodies, immunoassays, and others. Based on end-user, the global coxsackievirus diagnostics market can be divided into hospitals, commercial/private labs, physician offices, and public health labs. The commercial/private labs segment is likely to hold major share of the coxsackievirus diagnostics market due to availability of modern technology equipment for diagnosis and major hospitals and clinics send blood sample to private labs for diagnosis.
In terms of region, the global coxsackievirus diagnostics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2017, North America was a significant coxsackievirus diagnostics market in terms of revenue. The coxsackievirus diagnostics market in Europe is expected to expand at a rapid pace in the near future. The coxsackievirus diagnostics market in emerging regions such as Asia Pacific, Latin America, and Middle East & Africa is anticipated to expand at a robust pace between 2018 and 2026. This is due to growth of the health care industry and an aging population, which consequently would lead to increased patient population in these countries. India, China, and Brazil are expected to be rapidly growing markets, owing to increase in investments by governments in order to enhance health care facilities.
Major players operating in the global coxsackievirus diagnostics market include Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc. and Hologic Corporation.
Interested in this report?
Get a FREE Brochure now!
*Get Brochure (PDF) sent to your email within minutes
Complete the form below and we'll get back to you shortly.